Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Maraviroc,Atorvastatin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HealthBioAI Receives FDA Acceptance for Long COVID Trial with Selzentry® and Lipitor
Details : Selzentry (maraviroc) is a CCR5 co-receptor antagonist, in combination with Lipitor (atorvastatin) is being evaluated for the treatment of Long COVID/Post Acute Sequelae of COVID.
Product Name : Selzentry
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Maraviroc,Atorvastatin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable